Residency · Residency · Hematology Thrombosis

Thalassemia Syndromes

Introduction

The thalassemia syndromes are a heterogeneous group of inherited disorders characterized by decreased or absent production of one or more globin chains, resulting in an imbalanced ratio of alpha to beta globin subunits that drives the two central pathologic processes of the disease: ineffective erythropoiesis within the bone marrow and peripheral hemolysis of circulating red cells. Thalassemias represent the most common monogenic disorders worldwide, with more than 300 million carriers globally. Their geographic distribution reflects the selective pressure of endemic malaria, with the highest prevalence in the Mediterranean basin, the Middle East, the Indian subcontinent, Southeast Asia, and sub-Saharan Africa.

Molecular Basis

Normal Hemoglobin Structure

Normal adult hemoglobin is a tetrameric protein composed of two alpha-globin and two beta-globin chains. Hemoglobin A (alpha2-beta2) constitutes 95 to 97% of total adult hemoglobin, while hemoglobin A2 (alpha2-delta2) accounts for 2 to 3.5%, and fetal hemoglobin (HbF, alpha2-gamma2) is normally present at less than 1% in adults. The alpha-globin genes are located on chromosome 16, where two alpha-globin genes (HBA1 and HBA2) are present on each chromosome, yielding a total of four alpha-globin gene copies per diploid genome. The beta-globin gene (HBB) resides on chromosome 11, with one copy per chromosome and two copies per diploid genome. This difference in gene copy number has fundamental implications for the molecular genetics and clinical expression of alpha versus beta thalassemia.

Alpha-Thalassemia

Alpha-thalassemia is most commonly caused by gene deletions, in contrast to the point mutations that predominate in beta-thalassemia. Several well-characterized deletions account for the majority of cases worldwide. The rightward deletion (-alpha3.7) is the most common alpha-thalassemia allele globally, while the leftward deletion (-alpha4.2) is also frequently encountered. Larger deletions that remove both alpha-globin genes on a single chromosome include the Southeast Asian deletion (--SEA), the Mediterranean deletion (--MED), and the Filipino deletion (--FIL). Non-deletional forms of alpha-thalassemia also exist, the most clinically significant being hemoglobin Constant Spring (alpha-CS), which results from a stop codon mutation that produces an elongated and unstable alpha-globin chain. Hemoglobin Constant Spring is particularly common in Southeast Asian populations and is associated with a more severe phenotype when combined with a two-gene deletion.

Beta-Thalassemia

Beta-thalassemia is predominantly caused by point mutations, with more than 300 different mutations described to date. These mutations are classified based on their effect on beta-globin production: beta-zero (beta0) mutations result in complete absence of beta-globin production from the affected allele, while beta-plus (beta+) mutations result in reduced but not absent production. The molecular mechanisms include promoter region mutations that reduce transcription, splice site mutations that impair mRNA processing, nonsense mutations that introduce premature stop codons, and frameshift mutations that alter the reading frame. An important genetic modifier is the coinheritance of alpha-thalassemia, which ameliorates the severity of beta-thalassemia by reducing the degree of alpha/beta globin chain imbalance and thereby diminishing the excess of unpaired alpha chains that drive ineffective erythropoiesis.

Alpha-Thalassemia Clinical Spectrum

Silent Carrier (-alpha/alpha-alpha)

The silent carrier state results from a single alpha-globin gene deletion, leaving three functional alpha genes. Individuals with this genotype are completely asymptomatic and have a normal or at most minimally microcytic complete blood count. Hemoglobin electrophoresis is entirely normal because three alpha genes produce sufficient alpha-globin to maintain a normal alpha/beta ratio. Diagnosis can only be established through molecular genetic testing, which is typically performed in the context of genetic counseling when a partner is known or suspected to carry alpha-thalassemia.

Alpha-Thalassemia Trait (--/alpha-alpha or -alpha/-alpha)

Alpha-thalassemia trait results from the loss of two of the four alpha-globin genes, leaving two functional copies. Affected individuals demonstrate a mild microcytic hypochromic anemia with hemoglobin levels typically in the range of 11 to 13 g/dL and an MCV of 65 to 75 fL. The red cell distribution width (RDW) is characteristically normal, which is an important distinguishing feature from iron deficiency anemia, where the RDW is elevated. Hemoglobin electrophoresis and iron studies are both normal, which can create diagnostic confusion unless the clinician considers alpha-thalassemia in the differential.

A critically important distinction is whether the two-gene deletion is in the cis configuration (both deletions on the same chromosome, --/alpha-alpha) or the trans configuration (one deletion on each chromosome, -alpha/-alpha). The cis configuration is common in Southeast Asian populations and places offspring at risk for HbH disease or the lethal Hb Bart's hydrops fetalis syndrome when both parents carry the cis deletion. The trans configuration is common in individuals of African descent and is not associated with risk of Hb Bart's hydrops fetalis, because each chromosome retains at least one functional alpha gene. This distinction has profound genetic counseling implications.

HbH Disease (--/-alpha)

HbH disease results from the loss of three of four alpha-globin genes, leaving only one functional copy. The severe deficit of alpha chains leads to the formation of beta-globin tetramers (beta4), known as hemoglobin H, which constitute 5 to 30% of total hemoglobin on electrophoresis. HbH can be detected on supravital staining as characteristic "golf-ball" inclusions within red cells. The clinical phenotype is a moderate hemolytic anemia with hemoglobin levels typically in the range of 7 to 10 g/dL. HbH Constant Spring, in which the non-deletional Constant Spring mutation is combined with a two-gene deletion, produces a more severe phenotype with hemoglobin levels of 6 to 8 g/dL and greater transfusion requirements.

Patients with HbH disease commonly develop splenomegaly, jaundice, and pigment gallstones as consequences of chronic hemolysis. Iron overload may develop from both chronic transfusion therapy and increased intestinal iron absorption driven by ineffective erythropoiesis. Treatment includes daily folic acid supplementation, transfusions as clinically indicated, iron chelation therapy when overload is documented, and splenectomy for patients with significant hypersplenism contributing to worsening cytopenias.

Hb Bart's Hydrops Fetalis (--/--)

Hb Bart's hydrops fetalis results from the complete absence of functional alpha-globin genes. Without any alpha chains, the predominant hemoglobin produced is Hb Bart's (gamma4 tetramers), which has an extremely high oxygen affinity and is therefore unable to deliver oxygen effectively to tissues, resulting in profound tissue hypoxia. The clinical consequence is severe fetal anemia, massive hepatosplenomegaly from extramedullary hematopoiesis, generalized edema (hydrops), and typically intrauterine death or death within hours of birth. Maternal complications are also significant and include preeclampsia and severe postpartum hemorrhage.

Historically, Hb Bart's hydrops fetalis has been considered uniformly fatal and incompatible with life. However, intrauterine transfusion beginning in the second trimester, followed by postnatal hematopoietic stem cell transplantation, is emerging as a potential rescue strategy. This approach remains highly investigational and raises complex ethical considerations regarding long-term outcomes and quality of life for survivors.

<image>A clinical spectrum diagram showing the four levels of α-thalassemia (silent carrier, trait, HbH disease, Hb Bart's hydrops fetalis) and three levels of β-thalassemia (trait/minor, intermedia, major) arranged as a severity gradient from left to right. For each category, display: number of functional genes (for α-thal) or genotype (for β-thal), typical hemoglobin level, MCV range, key lab findings (HbA2, HbH, HbF levels), peripheral smear appearance (target cells, microcytosis, nucleated RBCs), and clinical manifestations (from asymptomatic to hydrops fetalis). Include small hemoglobin electrophoresis pattern diagrams for each category. At the bottom, show a geographic map highlighting prevalence regions for α-thal (Southeast Asia, Africa) and β-thal (Mediterranean, Middle East, South Asia). Medical textbook style with gradient color coding from green (mild) to red (severe).</image>

Beta-Thalassemia Clinical Spectrum

Beta-Thalassemia Minor (Trait)

Beta-thalassemia minor, or trait, is the heterozygous state in which one beta-globin allele carries a thalassemia mutation (either beta+ or beta0) while the other allele is normal. The clinical manifestation is a mild microcytic hypochromic anemia with hemoglobin levels of 10 to 12 g/dL and an MCV characteristically in the range of 60 to 70 fL. The diagnostic hallmark is an elevated hemoglobin A2 level, typically in the range of 3.5 to 7%, reflecting the compensatory increase in delta-globin chain production when beta-globin output is reduced. HbF may also be mildly elevated in the range of 1 to 5%. No treatment is required for beta-thalassemia trait itself, but genetic counseling is essential for reproductive planning, particularly when both partners carry beta-thalassemia mutations.

Beta-Thalassemia Intermedia (Non-Transfusion-Dependent, NTDT)

Beta-thalassemia intermedia encompasses a genotypically diverse group of patients who maintain hemoglobin levels of 7 to 10 g/dL without the need for regular transfusions. The genotypes include homozygous mild beta+ mutations, compound heterozygous states with ameliorating factors such as coinherited alpha-thalassemia or hereditary persistence of fetal hemoglobin, and other modifier combinations. Despite the absence of regular transfusion dependence, patients with thalassemia intermedia are at risk for a constellation of complications including extramedullary hematopoiesis (with paravertebral masses that can cause spinal cord compression), pulmonary hypertension, a significant thrombophilia (particularly in splenectomized patients), iron overload from increased intestinal absorption rather than transfusion alone, osteoporosis, and leg ulcers. Luspatercept has emerged as a treatment option that may reduce transfusion burden in this population.

Beta-Thalassemia Major (Transfusion-Dependent, TDT)

Beta-thalassemia major is the most severe clinical phenotype, resulting from homozygous beta0/beta0 mutations or severe beta+/beta0 compound heterozygous states. Clinical presentation typically occurs between 6 and 12 months of age, coinciding with the physiologic transition from fetal hemoglobin to hemoglobin A. Without treatment, patients develop severe anemia with hemoglobin levels of 3 to 5 g/dL, failure to thrive, and progressive hepatosplenomegaly. In the absence of adequate transfusion therapy, the massively expanded but ineffective erythroid marrow causes dramatic skeletal changes including frontal bossing, maxillary hyperplasia (producing the characteristic "chipmunk facies"), and the "hair-on-end" appearance on skull radiographs. Pathologic fractures and extramedullary hematopoietic masses are additional complications of untreated disease.

Management of Transfusion-Dependent Thalassemia

Chronic Transfusion Program

The goal of chronic transfusion therapy in transfusion-dependent thalassemia is to maintain the pre-transfusion hemoglobin level at 9.5 to 10.5 g/dL. This target is chosen because it effectively suppresses the patient's own ineffective erythropoiesis, prevents the skeletal changes that result from marrow expansion, and supports normal growth and development in children. Transfusions are typically administered every 2 to 4 weeks. Red cell units should be phenotype-matched at a minimum for Rh (C, c, E, e) and Kell antigens to reduce the risk of alloimmunization, and should be leukoreduced. For patients who are potential candidates for hematopoietic stem cell transplantation, CMV-safe blood products are preferred. Despite prophylactic phenotype matching, alloimmunization rates remain in the range of 5 to 30% among chronically transfused thalassemia patients, and extended antigen matching beyond Rh and Kell is increasingly adopted as standard practice.

Iron Overload and Chelation

Each unit of packed red blood cells contains approximately 200 to 250 mg of elemental iron, and the human body possesses no physiologic mechanism for excreting excess iron. Consequently, patients on chronic transfusion therapy inevitably develop progressive iron overload. Iron is deposited in the liver (causing hepatotoxicity and ultimately cirrhosis), the heart (causing cardiomyopathy, which has historically been the leading cause of death in thalassemia major), and the endocrine organs (causing diabetes mellitus, hypogonadotropic hypogonadism, hypothyroidism, and hypoparathyroidism).

Monitoring of iron overload requires a multimodal approach. Serum ferritin should be measured every 3 months, with a target of less than 1000 ng/mL, though ferritin is an imperfect surrogate that can be influenced by inflammation and liver disease. Liver iron concentration (LIC) is measured annually by MRI using R2 (FerriScan) or R2 methodology, with a target of less than 7 mg per gram dry weight. Cardiac iron is assessed by cardiac MRI T2 measurement, performed annually beginning at age 10. A T2* value below 20 milliseconds indicates cardiac iron loading, while a value below 10 milliseconds signifies severe loading with high risk of cardiomyopathy and arrhythmia.

Chelation Agents

Combination chelation with deferoxamine plus deferiprone is synergistic and is specifically indicated for patients with severe cardiac iron overload, defined by a cardiac T2* below 10 milliseconds. The rationale for combination therapy is that deferiprone mobilizes iron from cardiac myocytes and transfers it to deferoxamine in the plasma for excretion, a "shuttle" mechanism that provides more rapid cardiac iron removal than either agent alone.

Luspatercept (Reblozyl)

Luspatercept is a modified activin receptor IIA ligand trap that promotes late-stage erythroid maturation by binding and neutralizing TGF-beta superfamily ligands that normally inhibit terminal erythropoiesis. In the pivotal BELIEVE trial, 21% of patients with transfusion-dependent beta-thalassemia achieved at least a 33% reduction in transfusion burden compared to 4.5% in the placebo group. Luspatercept received FDA approval in 2019 for transfusion-dependent thalassemia and has also been approved for non-transfusion-dependent thalassemia and lower-risk myelodysplastic syndromes with ring sideroblasts. The drug is administered at a starting dose of 1 mg/kg subcutaneously every 3 weeks, with titration up to 1.25 mg/kg based on response. Side effects include bone pain, arthralgia, headache, and fatigue.

Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation remains the only established cure for beta-thalassemia major. The best outcomes are achieved when transplantation is performed from an HLA-matched sibling donor in young patients classified as Pesaro Class 1 or 2, with overall survival exceeding 90% and thalassemia-free survival exceeding 80%. The Pesaro classification system stratifies transplant risk based on three factors: liver size, degree of hepatic fibrosis, and adequacy of prior iron chelation. Haploidentical and matched unrelated donor transplantation have become increasingly successful with the adoption of post-transplant cyclophosphamide-based platforms, expanding the donor pool significantly. The optimal timing for transplantation is ideally before age 7 to 10 and before the development of significant iron overload or organ damage.

Gene Therapy

The approval of gene therapy products represents a transformative advance in thalassemia management. Exagamglogene autotemcel (Casgevy), a CRISPR-Cas9-based therapy that disrupts the BCL11A erythroid enhancer in autologous CD34+ hematopoietic stem cells to derepress fetal hemoglobin production, received FDA approval in December 2023 for transfusion-dependent thalassemia. In the CLIMB-111 trial, 91% of evaluable patients achieved transfusion independence for 12 or more months. Betibeglogene autotemcel (Zynteglo), a lentiviral vector-based gene addition therapy that delivers an anti-sickling beta-globin gene variant (betaA-T87Q), was FDA-approved in 2022. In phase 3 studies, 89% of patients with non-beta0/beta0 genotypes became transfusion-independent. Zynteglo carries a list price of $2.8 million as a one-time treatment, with an outcomes-based pricing model. Reports of hematologic malignancy potentially related to insertional mutagenesis have led to heightened long-term monitoring requirements. Both gene therapy products require myeloablative conditioning with busulfan, making fertility preservation counseling a critical component of the pre-treatment discussion.

<image>An iron overload monitoring and management algorithm for transfusion-dependent thalassemia. Start with "Chronic Transfusion Therapy" at the top. Show monitoring pathway: serum ferritin every 3 months plus annual liver MRI (R2/FerriScan for LIC) plus annual cardiac MRI T2 (starting age 10). Create decision branches based on LIC values: LIC <3 mg/g (reduce/hold chelation), 3-7 mg/g (maintain chelation), 7-15 mg/g (intensify chelation), >15 mg/g (urgent intensification). Separate branch for cardiac T2: >20 ms (no cardiac iron), 10-20 ms (cardiac iron loading, intensify chelation), <10 ms (severe cardiac risk, continuous IV DFO + oral DFP combination). Show the three chelation agents with their key properties in a comparison box. Include target values: ferritin <1000, LIC <7, T2* >20 ms. Clinical algorithm style with traffic-light color coding (green/yellow/red for severity).</image>

Key Clinical Pearls

• HbA2 elevation (>3.5%) is the hallmark of beta-thalassemia trait; concurrent iron deficiency can lower HbA2 into the normal range, masking the diagnosis - always replete iron before interpreting
• Alpha-thalassemia trait has a NORMAL Hb electrophoresis and cannot be diagnosed by standard methods; molecular testing is required
• The distinction between cis (--/alpha-alpha) and trans (-alpha/-alpha) deletion in alpha-thalassemia trait has critical genetic counseling implications; cis carriers can have children with Hb Bart's hydrops fetalis
• Cardiac iron overload (T2* <20 ms) is the leading cause of death in TDT; cardiac MRI monitoring is essential and should begin by age 10
• Deferiprone has superior cardiac iron chelation compared to deferoxamine and deferasirox; combination DFO + DFP is synergistic for severe cardiac iron loading
• Gene therapy represents a paradigm shift but requires careful patient selection, myeloablative conditioning, and long-term safety monitoring

References

1. Taher AT, et al. Thalassaemia. Lancet. 2018;391(10116):155-167.
2. Cappellini MD, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia (BELIEVE). N Engl J Med. 2020;382(13):1219-1231.
3. Thompson AA, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia (Zynteglo). N Engl J Med. 2018;378(16):1479-1493.
4. Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252-260.
5. Thalassaemia International Federation. Guidelines for the Management of Transfusion Dependent Thalassaemia (TIF), 4th Edition. 2021.

Read this lecture as Markdown